Research programme: influenza virus haemagglutinin glycoprotein inhibitors- PeptiDream/The Tokyo Metropolitan Institute of Medical Science

Drug Profile

Research programme: influenza virus haemagglutinin glycoprotein inhibitors- PeptiDream/The Tokyo Metropolitan Institute of Medical Science

Alternative Names: Hemagglutinin protein inhibitors - PeptiDream/The Tokyo Metropolitan Institute of Medical Science; iHA 24

Latest Information Update: 11 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PeptiDream
  • Developer PeptiDream; The Tokyo Metropolitan Institute of Medical Science
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza virus infections

Most Recent Events

  • 11 Apr 2014 PeptiDream and The Tokyo Metropolitan Institute of Medical Science collaborate to develop influenza virus haemagglutinin glycoprotein inhibitors for treatment of Influenza virus infections
  • 08 Apr 2014 Preclinical trials in Influenza-A virus H1N1 subtype in Japan (unspecified route)
  • 08 Apr 2014 Preclinical trials in Influenza-A virus H5N1 subtype in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top